Archive for the ‘Princeton spinoffs’ Category

BioNanomatrix (Princeton) to Introduce nanoAnalyzer® 1000 System (10/27/2010)

November 1, 2010

BioNanomatrix was co-founded by Princeton University professor Dr. Stephen Chou who developed a fast technology for sequencing DNA.

BioNanomatrix, Inc., which is developing and commercializing breakthrough single‐molecule genomic analysis technology, will introduce next month the nanoAnalyzer 1000 System at the American Society of Human Genetics (ASHG) Annual Meeting from November 2‐6, 2010 in Washington, D.C. read more


BioNanomatrix (Princeton) Founder and CSO Dr. Han Cao Awarded Chinese Rising Star Entrepreneur Award (10/7/2010)

October 11, 2010

BioNanomatrix is a Princeton-based spinoff developing nanoscale imaging and analytic technologies to analyze genomes.

BioNanomatrix, Inc., which is developing and commercializing breakthrough single-molecule genomic analysis technology, announced today that Founder and Chief Scientific Officer, Han Cao, Ph.D., was awarded the Chinese Rising Star Entrepreneur Award at the China International Economic and Technical Cooperation Forum in Beijing, China on September 27, 2010. The award is in recognition of Dr. Cao’s entrepreneurial spirit and success in the founding of BioNanomatrix and the development of the Company’s novel genomic analysis technology. [read more]

TetraLogic (Princeton) Expands Series C Financing with New Investor Pfizer Ventures (9/27/2010)

October 5, 2010

TetraLogic Pharmaceuticals is a Princeton spinoff that develops small molecule drugs to treat debilitating diseases and conditions

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that Pfizer Ventures has joined the syndicate of Series C investors with an investment of $5 million, increasing the amount of the Series C financing to $37 million. The initial Series C financing closing of $32 million was announced by TetraLogic Pharmaceuticals on August 10, 2010. The Series C financing was led by Clarus Ventures and included new investor Hatteras Venture Partners and existing investors Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group. [read more]